A universal low-dose multi-allergen immunotherapy (MAIT) regimen is well-tolerated and leads to remarkable improvements in symptoms of moderate to severe allergic rhinitis. This randomized double-blind pilot study was performed to determine the safety and effectiveness of an all-purpose, MAIT formulation for allergic rhinitis management. A new, subcutaneous MAIT regimen comprising a special combination of greater than 150 aeroallergens, encompassing several cross-reactive species, was administered in a double-blind, placebo-controlled study to individuals with moderate-severe perennial and seasonal allergic rhinitis.

Regardless of whatever specific skin tests were positive, every patient received the same universal immunotherapy regimen. The usage of rescue drugs, mini-Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), validated clinical evaluations, and the Total Nasal Symptom Score (TNSS) were the key endpoints at 8 and 12 weeks of treatment. In total, 31 individuals were randomly allocated to get MAIT or placebo. MAIT reduced the combined TNSS and rescue medication score (Daily Combined Score [DCS]) by -4.6 (-58%) as opposed to -1.5 (-20%) for the placebo (P = 0.037) by week 12.

The mini-RQLQ dropped by -34.9 (-68%) with MAIT when compared to -17 (-42%) with placebo. Mild adverse effects were rare and occurred with identical frequency in each arm. The symptoms of allergic rhinitis considerably improved after using a universal, global, high species abundance, MAIT formula. The outcomes of this study should be viewed as preliminary.